Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T17:53:19.337Z.
Calculation as of: 2026-10-06T17:53:19.337Z.
Quote observation: 2026-10-06T17:50:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2f01081ea3fc0a51e4cf91d063b31ee616ec5173ab430d737d4f5d2ff49fd95f
PEG RATIO
N/A
Spero Therapeutics, Inc.
Market Cap
$68.32M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | $68.32M | N/A |
| Tiziana Life Sciences Ltd (TLSA)vs › | $68.40M | N/A |
| iBio, Inc. (IBIO)vs › | $67.52M | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $68.27M | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $69.75M | N/A |
| XBiotech Inc. (XBIT)vs › | $66.46M | N/A |
| Cingulate Inc. (CING)vs › | $66.27M | N/A |
| MindWalk Holdings Corp. (HYFT)vs › | $72.36M | N/A |
| Gain Therapeutics, Inc. (GANX)vs › | $71.87M | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $64.49M | N/A |
PEG Ratio
N/A
P/E Ratio
10.7
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
